HQ
Columbus, OH
Founders and CEO
Richard Shea
Sector
Digital Health & Healthcare IT

Company Profile

Basking Biosciences is developing the first reversible thrombolytic therapy for acute ischemic stroke (AIS). The company’s development candidate, DTRI-031, is an RNA aptamer that inhibits von Willebrand Factor (vWF). Basking is co-developing a matched oligonucleotide reversal agent, DTRI-025, for as-needed, rapid reversal of DTRI-031. Basking’s paired therapy has the potential to significantly expand the population of patients that receive acute thrombolytic therapy and aligns perfectly with the urgent need in medicine for precision-based therapeutics in cardiovascular disease.

Blogs About Basking Biosciences

Basking Biosciences
Basking Bioscience Can Treat the 600,000 Stroke Victims Every Year
Welcoming Two New Startups to Rev1’s Investor Startup Studio
Investor Startup Studio